Biohit Oyj B
Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist … Read more
Biohit Oyj B (BIOBV) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.040x
Based on the latest financial reports, Biohit Oyj B (BIOBV) has a cash flow conversion efficiency ratio of 0.040x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€600.00K) by net assets (€14.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biohit Oyj B - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how Biohit Oyj B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Biohit Oyj B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biohit Oyj B ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nova EYE Medical Ltd
AU:EYE
|
-0.144x |
|
Dedicare AB
LSE:0P3K
|
0.133x |
|
Chander Electronics Corp.
TWO:8068
|
-0.081x |
|
Prime Financial Group Ltd
AU:PFG
|
0.036x |
|
Buriram Sugar Public Company Limited
BK:BRR
|
0.195x |
|
Elauwit Connection, Inc. Common Stock
NASDAQ:ELWT
|
-0.028x |
|
FARMAE S.P.A.
F:U5Y
|
N/A |
|
Force MOS Technology Co., LTD.
TWO:4923
|
0.083x |
Annual Cash Flow Conversion Efficiency for Biohit Oyj B (2000–2025)
The table below shows the annual cash flow conversion efficiency of Biohit Oyj B from 2000 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €14.90 Million | €-700.00K | -0.047x | -197.81% |
| 2024-12-31 | €12.20 Million | €586.00K | 0.048x | -49.81% |
| 2023-12-31 | €9.43 Million | €902.00K | 0.096x | -61.38% |
| 2022-12-31 | €7.46 Million | €1.85 Million | 0.248x | +507.40% |
| 2021-12-31 | €7.30 Million | €-444.00K | -0.061x | -2017.33% |
| 2020-12-31 | €8.70 Million | €-25.00K | -0.003x | -150.46% |
| 2019-12-31 | €14.58 Million | €83.00K | 0.006x | +197.28% |
| 2018-12-31 | €15.89 Million | €-93.00K | -0.006x | +89.30% |
| 2017-12-31 | €17.24 Million | €-943.00K | -0.055x | +76.07% |
| 2016-12-31 | €10.75 Million | €-2.46 Million | -0.229x | +25.12% |
| 2015-12-31 | €10.31 Million | €-3.15 Million | -0.305x | -12.65% |
| 2014-12-31 | €12.68 Million | €-3.44 Million | -0.271x | -36.91% |
| 2013-12-31 | €22.45 Million | €-4.44 Million | -0.198x | +20.99% |
| 2012-12-31 | €35.49 Million | €-8.89 Million | -0.250x | -367.03% |
| 2011-12-31 | €52.85 Million | €4.96 Million | 0.094x | -37.80% |
| 2010-12-31 | €13.00 Million | €1.96 Million | 0.151x | -31.23% |
| 2009-12-31 | €12.75 Million | €2.80 Million | 0.219x | +130.61% |
| 2008-12-31 | €12.49 Million | €1.19 Million | 0.095x | +8.29% |
| 2007-12-31 | €11.84 Million | €1.04 Million | 0.088x | +1078.15% |
| 2006-12-31 | €13.41 Million | €100.00K | 0.007x | -82.44% |
| 2005-12-31 | €14.25 Million | €605.00K | 0.042x | -73.18% |
| 2004-12-31 | €14.14 Million | €2.24 Million | 0.158x | +158.63% |
| 2003-12-31 | €14.10 Million | €863.00K | 0.061x | -46.71% |
| 2001-12-31 | €16.33 Million | €1.88 Million | 0.115x | +110.71% |
| 2000-12-31 | €98.02 Million | €5.34 Million | 0.055x | -- |